Annalee Armstrong

Biopharma deal activity plummeted down to Earth in the second quarter, with just a handful of M&A transactions and IPOs studding the mostly dark skies.

Amylyx's co-CEOs Josh Cohen and Justin Klee have already had to make what may end up being the toughest decision of their careers: withdrawing

The obesity game is only in its early innings, and the future market will be defined by who can ease administration of the medicines, according to a new report from Evaluate.

Welcome to this week's Chutes & Ladders, our roundup

Allarity Therapeutics has received notice from the Securities and Exchange Commission that an enforcement action is pending regarding FDA meetings the biotech had surrounding the new drug applicati

Revenue for clinical research services company IQVIA was boosted by 2.3% in the second quarter compared to the prior-year period, thanks to

Pinetree Therapeutics will help AstraZeneca plant some trees in its pipeline with a new pact to develop a preclinical EGFR degrader worth $45 million upfront for the small biotech.

After reaching out to more than 200 companies to partner a Tourette syndrome therapy that showed the ability to beat standard of care last year, Asarina Pharma has come up empty and will fold.

Viking Therapeutics will launch a long ship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million.

In this week's episode of "The Top Line," Fierce Biotech's Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014.